vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
20 févr. 2020 18h57 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an...
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
10 févr. 2020 07h00 HE
|
vTv Therapeutics Inc.
- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor...
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
07 févr. 2020 16h05 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial...
vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
02 déc. 2019 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
30 oct. 2019 17h30 HE
|
vTv Therapeutics Inc.
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT,...
vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
03 oct. 2019 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing...
vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
18 sept. 2019 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1...
vTv Therapeutics to Present Posters at Two Scientific Conferences in September
11 sept. 2019 07h30 HE
|
vTv Therapeutics Inc.
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program HIGH POINT, N.C., Sept. 11, 2019 (GLOBE...
vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
04 sept. 2019 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences
06 août 2019 16h05 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered...